IFI35 and renal carcinoma: Compared with control treatment, 3-MA treatment significantly reduced the expression levels of LC3-II and the rate of LC3-II/LC3-I in IFI35 shRNA-treated Ketr-3 or 786-O cells (Figure 6A,B), implying that the inhibitor could effectively suppress autophagy formation induced by IFI35 knockdown in renal cancer cells.